With the expansion of use, it is estimated that half of the patients who use vitaminD analogues would be indicated for cinacalcet because they have PTH above 500 pg/mLin the presence of hyperphosphatemia or hypercalcemia or because they do not reachthe PTH target value, between 150–300 pg/mL with the use of at least 0.1 ucg/kg/doseof paricalcitol 3 times a week or even for having a kidney transplant with PTH >120 pg/mL. This evidence concerns the gene PTH and hypercalcemia disease.